Quantcast

Industry news that matters to you.  Learn more

DHMRI and Metabolon Announce Strategic Partnership to Provide Expanded Metabolomics Capabilities

The David H. Murdock Research Institute (DHMRI) at the North Carolina Research Campus and Metabolon, Inc., recently announced that they have entered into a strategic agreement to align metabolomics research services. Metabolon is a pioneering leader in discovery metabolomics and specializes in rapidly assessing metabolism in biological samples to quickly identify prospective biomarkers and to understand metabolic effects of treatments, interventions, nutritionals, etc. The agreement complements DHMRI’s mass spectrometry and NMR‐based metabolomics services through access to Metabolon’s industry‐leading high‐throughput biomarker discovery and profiling platform which provides an extensive, untargeted, broad metabolite survey of more than 4000 biochemicals.

“This agreement leverages the strengths of our organizations to best serve DHMRI collaborators to understand metabolism and ultimately answer key research questions and deliver healthy food products for consumers. We have worked extensively in food science and nutrition and recognize that our combined resources are indeed complementary. DHMRI is a center of excellence in nutrition research and we are delighted to do our part to meet their growing needs,” says Chris Bernard, senior Vice President of Sales & Marketing for Metabolon.

DHMRI is an established not‐for‐profit research institute that provides flexible, client‐focused research services to academia, government and industry collaborators. This agreement,
consistent with the DHMRI’s collaborative approach to scientific inquiry, provides partners with additional resources for metabolomics. Metabolon’s global metabolomic approach can
pinpoint active pathways which can be further interrogated by targeted and or customized approaches offered by the DHMRI Metabolomics team.

“We are excited to broaden the breadth of services offered by the DHMRI to our collaborators. The benefits stemming from the collective knowledge of our organizations will be readily
realized by researchers, companies and consumers,” said Steve Lommel Ph.D., Interim President, David H. Murdock Research Institute.

Source: David H. Murdock Research Institute

LabCorp Clinical Trials, DHMRI Form Strategic Alliance to Offer Specialized Biomarker and Assay Development Services

Esoterix Clinical Trials Services, a division of Laboratory Corporation of America Holdings (LabCorp), today announced a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services. Assays developed at DHMRI for contracted research will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.

DHMRI Establishes Immune Monitoring Laboratory for Biomarker Discovery and Development

Last week, the David H. Murdock Research Institute (DHMRI) announced that it acquired the Immune Tolerance Institute, Inc. (ITI) as a next step in its continued growth. The DHMRI provides integrated, state-of-the-art genomic, cellular, proteomic and bioinformatics technology platforms as a major resource for a range of academic and industry partners undertaking both preclinical and clinical research.